Related references
Note: Only part of the references are listed.Measurements of Immune Responses for Establishing Correlates of Vaccine Protection Against HIV
Wendy A. Burgers et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2012)
DNA and Modified Vaccinia Virus Ankara Vaccines Encoding Multiple Cytotoxic and Helper T-Lymphocyte Epitopes of Human Immunodeficiency Virus Type 1 (HIV-1) Are Safe but Weakly Immunogenic in HIV-1-Uninfected, Vaccinia Virus-Naive Adults
Geoffrey J. Gorse et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
David C. Montefiori et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
Dan H. Barouch et al.
NATURE (2012)
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses
Dennis R. Burton et al.
SCIENCE (2012)
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge
Josephine H. Cox et al.
VACCINE (2012)
HIV vaccine development: Challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem
Wayne C. Koff
VACCINE (2012)
Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination
Celine Verheust et al.
VACCINE (2012)
The changing face of HIV vaccine research
Peter D. Kwong et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2012)
AIDS Vaccines and Preexposure Prophylaxis: Is Synergy Possible?
Jean-Louis Excler et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2011)
Thirty Years of HIV and AIDS: Future Challenges and Opportunities
Carl W. Dieffenbach et al.
ANNALS OF INTERNAL MEDICINE (2011)
Living in a house of cards: re-evaluating CD8(+) T-cell immune correlates against HIV
George Makedonas et al.
IMMUNOLOGICAL REVIEWS (2011)
HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable
Stephen C. De Rosa et al.
JOURNAL OF IMMUNOLOGY (2011)
Long-Term Control of Simian Immunodeficiency Virusmac251 Viremia to Undetectable Levels in Half of Infected Female Rhesus Macaques Nasally Vaccinated with Simian Immunodeficiency Virus DNA/Recombinant Modified Vaccinia Virus Ankara
Mariana Manrique et al.
JOURNAL OF IMMUNOLOGY (2011)
Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
Paul A. Goepfert et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell Responses in Intestinal Mucosa
Matthieu Perreau et al.
JOURNAL OF VIROLOGY (2011)
In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers
Sandhya Vasan et al.
PLOS ONE (2011)
Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review
Marc P. Girard et al.
VACCINE (2011)
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects
Michael C. Keefer et al.
VACCINE (2011)
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pot and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
Felipe Garcia et al.
VACCINE (2011)
High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation
Jiangmei Yin et al.
VACCINE (2011)
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania
Muhammad Bakari et al.
VACCINE (2011)
Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1
Peter D. Kwong et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2011)
Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo
Natalie A. Hutnick et al.
CURRENT OPINION IN VIROLOGY (2011)
Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination
M. Juliana McElrath et al.
IMMUNITY (2010)
Lessons Drawn From Recent HIV Vaccine Efficacy Trials
Jonathan D. Fuchs et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
DNA Vaccines: Developing New Strategies against Cancer
Daniela Fioretti et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2010)
Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV-1 Vaccine Candidates
Aggeliki Spentzou et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Comparative Cell-Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIV-1 Clade B gag Vaccine Prime-Boost Regimens
David M. Asmuth et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination
Stephanie A. Freel et al.
JOURNAL OF VIROLOGY (2010)
Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses
Richard A. Koup et al.
PLOS ONE (2010)
Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B′ HIV-1 Candidate Vaccine
Sandhya Vasan et al.
PLOS ONE (2010)
Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa
Walter Jaoko et al.
PLOS ONE (2010)
Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories
Dilbinder K. Gill et al.
PLOS ONE (2010)
Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate
Jeffrey R. Currier et al.
PLOS ONE (2010)
Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects
Sarah Howles et al.
VACCINE (2010)
Poxvirus vector-based HIV vaccines
Giuseppe Pantaleo et al.
CURRENT OPINION IN HIV AND AIDS (2010)
HIV vaccines: lessons learned and the way forward
Jerome H. Kim et al.
CURRENT OPINION IN HIV AND AIDS (2010)
A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers
Vadakkuppatu Devasenapathi Ramanathan et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2009)
Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents
Mark J. Boaz et al.
CLINICAL AND VACCINE IMMUNOLOGY (2009)
Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS
Mariano Esteban
HUMAN VACCINES (2009)
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity
Lindvi Gudmundsdotter et al.
VACCINE (2009)
DNA-MVA vaccine protection after x4 SHIV challenge in Macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory
Mariana Manrique et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2008)
Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant
Taoxing Huang et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
Alexandre Harari et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Broad Immunogenicity of a Multigene, Multiclade HIV-1 DNA Vaccine Boosted with Heterologous HIV-1 Recombinant Modified Vaccinia Virus Ankara
Eric Sandstrom et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
EV02:: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone
Sheena McCormack et al.
VACCINE (2008)
Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challenge
Sharon E. Frey et al.
VACCINE (2007)
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity
Barry S. Peters et al.
VACCINE (2007)
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
Barney S. Graham et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults
M. J. Mulligan et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2006)
Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 gag coupled to CD8+ T-cell epitopes
Nilu Goonetilleke et al.
JOURNAL OF VIROLOGY (2006)
Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model
SS Rao et al.
VACCINE (2006)
Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates
FMN Bertley et al.
JOURNAL OF IMMUNOLOGY (2004)
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
DD Richman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine
RR Amara et al.
JOURNAL OF VIROLOGY (2002)
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays
JR Currier et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2002)
Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination
DH Barouch et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
